Abstract:OBJECTIVE: To explore whether Val279Phe single nucleotide polymorphisms (SNPs) in the 9th exon of platelet-activating factor acetylhydrolase (PAF-AH) are associated with intracranial hemorrhage in preterm infants. METHODS: A case-control study was performed. Polymerase chain reaction (PCR) was used to test genotype and allele frequencies of the 9th exon Val279Phe SNPs of PAF-AH in 58 preterm infants with intracranial hemorrhage (hemorrhage group) and 65 preterm infants without intracranial hemorrhage (control group). RESULTS: There were significant differences in genotype frequency of Val279Phe SNPs in the 9th exon of PAF-AH between the hemorrhage and control groups (P<0.05). Frequency of normal genotype in the hemorrhage group (63.8%) was significantly lower than in the control group (81.5%). In contrast, frequency of heterozygous genotype (34.5%) in the hemorrhage group was significantly higher than in control group (16.9%). There were also significant differences in allele frequency of Val279Phe SNPs in the 9th exon of PAF-AH between the two groups (P<0.05). T allele frequency in the hemorrhage group (19.0%) was significantly higher than in the control group (10.0%). CONCLUSIONS: Val279Phe SNPs in the 9th exon of PAF-AH may be associated with intracranial hemorrhage in preterm infants.
ZHANG Qian,CHENG Xin-Ru,XU Shu-Ling et al. Association between platelet-activating factor acetylhydrolase gene polymorphism and intracranial hemorrhage in preterm infants[J]. CJCP, 2012, 14(08): 612-615.
[1]Yoshida H, Imaizumi T, Fujimoto K, Itaya H, Hiramoto M, Yoshimizu N, et al. A mutation in plasmaplatelet-activating factor acetylhydrolase (Val279-Phe) is a genetic risk factor for cerebral hemorrhage but not for hypertension[J].Thromb Haemost, 1998, 80(3): 372-375.
[2]Hiramoto M, Yoshida H, Imaizumi T, Yoshimizu N, Satoh K. A mutationin plasma platelet-activating factor acetylhydrolase (Val279-Phe) is a genetic risk factor for stroke[J]. Stroke, 1997, 28(12): 2417-2420.
[5]Ito S, Noguchi E, Shibasaki M, Yamakawa-Kobayashi K, Watanabe H, Arinami T. Evidence for an association between plasma platelet-activating factor acetylhydrolase deficiency and increased risk of childhood atopic asthma[J]. J Hum Genet, 2002, 47(2): 99-101.
[6]Zhou X, He P. Temporal and spatial correlation of platelet-activating factor-induced increases in endothelial [Ca2+]i, nitric oxide, and gap formation in intact venules[J]. Am J Physiol Heart Circ Physiol, 2011, 301(5): H1788-H1797.
[7]Yang Y, Yin J, Baumgartner W, Samapati R, Solymosi EA, Reppien E, et al. Platelet-activating factor reduces endothelial nitric oxide production: role of acid sphingomyelinase[J]. Eur Respir J, 2010, 36(2): 417-427.
[8]程欣茹.PAF及PAF-AH在早产儿颅内出血中的变化及其临床意义[D].郑州大学,2012.
[9]Sekuri C, Cam FS, Tengiz I, Ercan E, Bayturan O, Berdeli A. Association of platelet-activating factor acetylhydrolase gene polymorphism with premature coronary artery disease in Turkish patients[J]. Anadolu Kardiyol Derg, 2006, 6(2): 132-134.
[11]Stafforini DM, Satoh K, Atkinson DL, Tjoelker LW, Eberhardt C, Yoshida H, et al. Platelet-activating factor acetylhydrolase deficiency. A missensemutation near the active site of an anti-inflammatory phospholipase[J]. J Clin Invest, 1996, 97(12): 2784-2791.
[12]Karabina SA, Gora S, Atout R, Ninio E. Extracellular phospholipases in atherosclerosis[J]. Biochimie, 2010, 92(6): 594-600.
[15]Stremler KE, Stafforini DM, Prescott SM, Zimmerman GA, McIntyre TM. An oxidized derivative of phosphatidylcholine is a substrate for the platelet-activating factor acetylhydrolase from human plasma[J]. J Biol Chem, 1989, 264(10): 5331-5334.
[16]Livnat I, Finkelshtein D, Ghosh I, Arai H, Reiner O. PAF-AH Catalytic Subunits Modulate the Wnt Pathway in Developing GABAergic Neurons[J]. Front Cell Neurosci, 2010, 4: 19.
[17]Glaw JT, Skalak TC, Peirce SM. Inhibition of canonical Wnt signaling increases microvascular hemorrhaging and venular remodeling in adult rats[J]. Microcirculation, 2010, 17(5): 348-357.